

In re Douglas et al.

Filed: 07/12/2001

Titled: METHODS AND COMPOSITIONS FOR  
CONTROLLING PROTEIN ASSEMBLY  
OR AGGREGATION

Application No.: 09/904,987

Group Art Unit 1614

Attorney Ref.: 42108/26146

#3  
TECH CENTER 1600/2900

OCT 02 2001

RECEIVED

Commissioner for Patents  
U.S. Patent and Trademark Office  
Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATION CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures of August 29, 2001, please accept the following remarks and enter the enclosed initial paper copy Sequence Listing, and diskette containing the same into the record of the above-referenced patent application.

REMARKS

In the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures of August 29, 2001, Applicant was required to comply with the requirements of C.F.R. §1.821-1.825. Specifically, Applicant was required to provide an initial computer readable form copy of the "Sequence Listing," an initial paper or compact disk copy of the "Sequence Listing," an amendment directing its entry into the application, and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written sequence listing and that no new matter was included. Accordingly, Applicant hereby states that the content of the sequence listing information recorded on the enclosed diskette, which is in a computer readable form, is identical to the paper sequence listing also included herewith, and includes no new matter, as

required by 37 C.F.R. §§1.821(e)-(g), 1.825(b), and 1.825(d). In addition, please enter the enclosed paper Sequence Listing and diskette containing the same into the record of the present application.


Accordingly, Applicant submits that the above-referenced patent application is in compliance with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. If the application, as amended herein, has not been brought into compliance with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, it is hereby requested that the Examiner contact the Applicant's undersigned attorney by telephone at (314) 552-6123, or by facsimile at (314) 552-7123. All correspondence should continue to be directed to my address given below.

Respectfully submitted,

Thompson Coburn LLP

By Ahaji K. Amos

AHAJI K. AMOS  
Registration No.: 46,831  
One Firststar Plaza  
St. Louis, MO 63101  
(314) 552-6123  
(314) 552-7123 FAX



1614 Bel Se

TRANSMITTAL LETTER  
(General - Patent Pending)

Docket No.  
42108/26146

TECH CENTER 1600/2900

OCT 02 2001

RECEIVED

In Re Application Of:  
Douglas et al

Serial No. 09/904,987	Filing Date 7/12/01	Examiner not yet assigned	Group Art Unit 1614
--------------------------	------------------------	------------------------------	------------------------

Title:  
METHOD AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS

Transmitted herewith is:  
Response to Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; Sequence Listing on 3 1/2 diskette; copy of the August 29, 2001 Notice To Comply with Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures from the US PTO and postcard.

in the above identified application.


- ☒ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 20-0823 as described below. A duplicate copy of this sheet is enclosed.
  - ☐ Charge the amount of \_\_\_\_\_
  - ☒ Credit any overpayment.
  - ☒ Charge any additional fee required.


Ahaji K. Amos  
Signature

Dated: 9-25-01

Ahaji K. Amos, Reg. No. 46,381  
Thompson Coburn LLP, One Firstar Plaza, St. Louis, MO 63101  
314-552-6123 (phone) and 314-552-7123 (fax)

cc: 021888

I certify that the document and fee is being deposited on 9-25-01 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.	
 Signature of Person Mailing Correspondence	
Eileen L. Curran Typed or Printed Name of Person Mailing Correspondence	



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

RECEIVED  
Page 1 of 2  
OCT 02 2001  
TECH CENTER 1600/2900

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/904,987	07/12/2001	Michael G. Douglas	42108/26146

021888  
THOMPSON COBURN, LLP  
ONE FIRSTAR PLAZA  
SUITE 3500  
ST LOUIS, MO 63101

RECEIVED

SEP 04 2001

Thompson Coburn LLP

CONFIRMATION NO. 3819

FORMALITIES LETTER



\*OC000000006493849\*

Date Mailed: 08/29/2001

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

*AB*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE